ProBiotix Health (PBX) | AQSE:PBX

ProBiotix Health reported a swing to EBITDA and net profit alongside 53% Revenue growth in its first-half results, yet the thinly traded AQSE stock has remained highly volatile, underscoring how Illiquid small-cap shares can move sharply on modest volumes even when the underlying numbers improve.

What happened

ProBiotix Health (AQSE: PBX), the probiotics and cardiometabolic health group behind the LPLDL patented strain, told investors on 6 August 2026 that revenue for the six months to 30 June 2026 rose 53% to £2.059 million, up from £1.344 million a year earlier, alongside a swing to a small EBITDA profit of £151,000 from a £112,000 loss in H1 2025.

On paper, that is a strong set of numbers for a small-cap life sciences company: gross Margin expanded to 60.4% from 55.7%, operating profit turned positive at £79,000, and the group posted a maiden net profit of £86,000 versus a £150,000 loss the year before. Basic Earnings Per Share moved to 0.05p from a loss of 0.09p.

Yet PBX shares, which trade on the Apex segment of the Aquis Stock Exchange rather than the main London Stock Exchange, have been unusually volatile in the days around the results. The stock is thinly traded — some sessions see only a handful of trades worth a few thousand pounds in total — so even modest order flow can swing the price sharply, and single-day percentage moves should be treated with caution.

For a company that has spent two years narrowing losses and chasing scale, the disconnect between improving fundamentals and a jumpy share price is the story worth unpacking.

Latest company news

The interim results, published via RNS on 6 August 2026, capped a busy summer of newsflow. On 23 July 2026, ProBiotix announced a new commercial Partnership with Belgium-based nutraceutical company Nutrisan, under which ProBiotix supplies its patented LPLDL probiotic strain for a finished-formulation product sold under the Nutrisan PRO Brand to pharmacists and healthcare professionals.

That followed a strategic alliance covering Spain and Portugal (26 May 2026) and a new partnership in Slovakia (1 June 2026), continuing a pattern of incremental European distribution deals. The company also held its AGM on 23 June 2026. Management pointed to a strengthening pipeline: the interim statement noted five new partnerships signed in H1 2026 and active customer growth of more than 15%.

Geographically, the US remains by far the largest market and carries meaningful customer concentration, while China — served through a Kemin Industries Supply partnership — and the broader Asia-Pacific and EMEA regions were flagged by chief executive Steen Andersen as the areas expected to drive further growth in H2 2026 and into 2027.

Financial position

ProBiotix's interim Balance Sheet shows a Business that is still small in absolute terms but improving in quality. Revenue of £2.059 million compares with £1.344 million in H1 2025, a 53% increase, while Gross Profit rose 66% to £1.245 million as margins improved to 60.4% from 55.7%.

The EBITDA swing — from a £112,000 loss to a £151,000 profit, excluding share-based payments — is the headline metric management emphasised, alongside the shift to operating profit (£79,000) and net profit (£86,000). Cash at period end stood at around £1.2-1.3 million, broadly stable versus a year earlier.

There are 158.2 million shares in issue, giving a Market Capitalisation that has fluctuated between roughly £11 million and £15 million in recent weeks depending on which trade prints are used — a reflection of how illiquid the stock is. Some third-party data providers flag a limited cash runway on current burn rates and note the board currently has no independent non-executive directors, points investors may wish to verify directly with the company.

The group pays no Dividend and has historically relied on Equity issuance to fund Working Capital since demerging from OptiBiotix Health's probiotics division. No new fundraising was announced alongside the interim results, but the modest cash balance relative to growth ambitions means further capital needs cannot be ruled out.

Why the shares may be under pressure

There is no single confirmed catalyst for any recent share-price weakness, and investors should be wary of assuming the interim results themselves triggered a sell-off — the numbers were, on their face, positive. What is clear is that PBX is an extremely thinly traded AQSE-listed micro-cap, where a small number of trades can produce outsized percentage swings that do not necessarily reflect a considered re-rating of the business.

Possible contributing factors include profit-taking after a strong run in the shares over the prior month; residual caution about customer concentration, with roughly half of group revenue tied to a single US customer; and broader small-cap sentiment, given the stock carries no analyst coverage to anchor expectations. Governance considerations flagged by some data providers, including board composition, may also weigh on institutional appetite. Because Liquidity is so low, bid-offer spreads can be wide, and headline price-change figures from different data providers have varied materially in recent days — a sign that any single day's move should be read with caution.

Bull case

The clearest positive is that ProBiotix has shown an improving profitability trajectory, moving from EBITDA losses to a small EBITDA profit while growing revenue by more than half. If the pattern of new distribution partnerships — five signed in H1 2026 alone, spanning Belgium, Slovakia and Iberia — continues to convert into recurring sales, the Operating Leverage in a high-margin, asset-light licensing and supply model could compound quickly.

The Kemin partnership in China and broader APAC push offer geographic Diversification away from US customer concentration, while continued clinical research into LPLDL's applications for prediabetes and diabetes management could, if successful, open new addressable markets.

Bear case

The business remains small, with roughly £2 million of half-year revenue and net profit measured in the tens of thousands of pounds — a scale at which single contract wins or losses can swing results materially. Customer concentration is a real risk: one customer accounted for close to half of group revenue in H1 2026.

Cash resources are modest relative to the company's growth ambitions, and further equity dilution to fund expansion cannot be excluded. Extremely low trading liquidity on AQSE also means existing and prospective shareholders may struggle to enter or exit positions at stable prices, amplifying Volatility independent of fundamentals.

What investors should watch next

Near-term catalysts include further updates on the pace of new partnership signings following the Belgium, Slovakia and Iberia deals, and progress converting the APAC and EMEA pipeline that management flagged as the key H2 2026 growth driver.

Investors should also watch for the full-year trading update and results, typically released in the following year based on the company's historical reporting calendar, for confirmation of whether the H1 profitability swing is sustained. Progress on the LPLDL clinical research programme in prediabetes and diabetes, any change in customer concentration, and the company's cash position, funding plans and board composition are all worth monitoring.

Conclusion

(AQSE:PBX) ProBiotix Health's interim results provide genuine evidence of operational progress: faster revenue growth, expanding margins, and a first swing into EBITDA and net profit. That the shares have nonetheless traded with notable volatility is best explained, on current evidence, by the stock's very thin liquidity on the Aquis Exchange rather than any clear market rejection of the results.

For prospective investors, the key questions are less about the headline growth rate and more about durability — can the recent run of European partnership deals convert into diversified, Recurring Revenue that reduces reliance on one large US customer, and can the company fund its next growth phase without material dilution. This article is for information purposes only and does not constitute personalised financial advice; readers should conduct their own research before making Investment decisions.